

NEOGEN CORP  
Form 8-K  
July 27, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of**

**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) July 21, 2016**

**NEOGEN CORPORATION**

**(Exact name of registrant as specified in its charter)**

**MICHIGAN**  
**(State or other jurisdiction**  
**of incorporation)**

**0-17988**  
**(Commission**  
**File Number)**

**38-2367843**  
**(IRS Employer**  
**Identification No.)**

**620 Leshier Place Lansing, Michigan**  
**(Address of principal executive offices)**

**48912**  
**(Zip Code)**

**Registrant's telephone number, including area code 517-372-9200**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On July 21, 2016, Dr. Clayton Yeutter informed the Board of Directors of the Company that he would not stand for re-election as a member of the Board when his current term expires in October 2016.

Dr. Yeutter, 86, has been a member of the Board of Directors since 2007 and is not standing for re-election for personal reasons. The Company advises that the Board of Directors expects to present a nominee to succeed Dr. Yeutter on the Board; this nominee is expected to be included in the Company's proxy statement, which will be mailed to shareholders at the end of August 2016.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

None

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOGEN CORPORATION  
(Registrant)

Date: July 27, 2016

/s/ Steven J. Quinlan  
Steven J. Quinlan  
Vice President & CFO